Skip to main content
Kent Academic Repository

Investigating the genomic basis for cancer cell response to multi-AGC kinase inhibitor AT13148

Hanly, David (2015) Investigating the genomic basis for cancer cell response to multi-AGC kinase inhibitor AT13148. Master of Science by Research (MScRes) thesis, University of Kent,. (doi:10.22024/UniKent/01.02.51029) (Access to this publication is currently restricted. You may be able to access a copy if URLs are provided) (KAR id:51029)

Language: English

Restricted to Repository staff only
[thumbnail of 227MSc Thesis David Hanly.pdf]
Official URL:


The PI3K-AKT cellular growth and survival signalling pathway is commonly deregulated in a wide range of cancers. The novel candidate anticancer drug AT13148 is a multi-AGC kinase whose targets include PI3K-AKT signalling effectors, and it is currently in phase I clinical trial. Recently, growth inhibition and gene mutation data for this compound have been produced from the Genomics of Drug Sensitivity in Cancer (GDSC) cell line panel at the Wellcome Trust Sanger Institute. When bioinformatics pharmacogenomic analyses were performed for common cancer genes, PTEN mutations were statistically significantly associated with AT13148 sensitivity, whereas KRAS mutations were significantly associated with resistance. Amplifications of KIT and PDGFRA, both individually and together with KDR were associated with potent AT13148 sensitivity. Whole exome pharmacogenomic analyses also revealed a further fifteen genes mutationally associated with sensitivity to AT13148, including VHL mutations predominantly in kidney cancer cell lines and rare mutations in CETN3, NOP10 and CLDND2 occurring in highly sensitive cell lines. IC50 comparison analyses between AT13148 and other drugs included on the GDSC database, SRC inhibitors Dasatinib, AZD-0530 and A-770041 gave strong IC50 correlations with AT13148 in kidney cancer cell lines. Future genomic analyses of AT13148 GDSC data should investigate the mutational characteristics of AT13148-sensitive PTEN mutated cell lines and further examine the genomic features of AT13148-responsive kidney cancer cell lines. Transcriptomics analysis approaches should also be developed and integrated into these investigations. Laboratory experiments should also be developed to test the pharmacogenomic associations with AT13148 response predicted in this study using a distinct set of cell lines. Results of such experiments, if consistent with predictions, may potentially assist with patient stratification for phase II clinical trial of AT13148.

Item Type: Thesis (Master of Science by Research (MScRes))
Thesis advisor: Wass, Mark N.
Thesis advisor: Michaelis, Martin
DOI/Identification number: 10.22024/UniKent/01.02.51029
Additional information: The author of this thesis has requested that it be held under closed access. We are sorry but we will not be able to give you access or pass on any requests for access. 11/05/2022
Uncontrolled keywords: Cancer; Cell signalling; Genomics; Pharmacogenomics; AGC kinase; Mutation; Growth inhibition; Targeted anticancer therapy; Bioinformatics; Drug response; Cell line; Chi-squared test
Subjects: Q Science > QP Physiology (Living systems)
Divisions: Divisions > Division of Natural Sciences > Biosciences
Depositing User: Users 1 not found.
Date Deposited: 14 Oct 2015 21:00 UTC
Last Modified: 28 Jul 2022 09:02 UTC
Resource URI: (The current URI for this page, for reference purposes)

University of Kent Author Information

Hanly, David.

Creator's ORCID:
CReDIT Contributor Roles:
  • Depositors only (login required):

Total unique views for this document in KAR since July 2020. For more details click on the image.